BETA: Please send your feedback!
Intercept Pharmaceuticals
ICPT:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2022
—
About
Pharmaceuticals: Other
Founded 2002
Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
website
Headquarters
Executives
| Name | Title | Gender |
| David A. Shapiro, MD | Chief Medical Officer & Executive VP-Development | Male |
| Mark E. Pruzanski, MD | President, Chief Executive Officer & Director | Male |
| Paolo Fundar | Chairman | Male |
| Roberto Pellicciari, PhD | Founder | Male |
| Mark J. Vignola, PhD | Director-Investor Relations | Male |
| Sandip S. Kapadia, MBA, CPA | Chief Financial Officer | Male |
| Jerome B. Durso | Chief Operating Officer | Male |
Mindful Investing Summary
Intercept Pharmaceuticals - Competitors and Related Companies
How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Intercept Pharmaceuticals
ICPT:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2022
—
MediciNova
MNOV:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Conatus Pharmaceuticals
CNAT:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Enzon Pharmaceuticals
ENZN:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—